“The Future of R&D Outsourcing”
R&D outsourcing is a widespread “norm” for both large and small companies. What began as a cost savings in manufacturing and services has now become a strategy to gain efficiencies and to enter growing markets. This globalization allowed companies to re-purpose resources to keep up with technology and influence product innovation. How will companies fare in the “new norm”? Is more outsourcing expected? Join speakers Dr. Bruce Molino and Mr. Christopher Conway as they map the future of R&D outsourcing from the science and business perspectives.
What You Will Learn
- Factors driving demand for R&D outsourcing
- Evolutionary pressures on way R&D outsourcing is done
- Future R&D outsourcing trends/Innovative business models
- And much more…
Date: Thursday, October 6, 2011
Time: 2:00-3:00 pm ET
Meet Your Experts
Dr. Bruce Molino is Senior Director of Medicinal Chemistry at AMRI which has R&D contract research services in the United States, Europe and Asia. There he manages contract drug discovery teams in pursuit of novel drug molecules for a range of diseases and therapeutic areas. Dr. Molino played a leadership role in an AMRI drug discovery collaboration with Bristol-Myers Squibb which led to human clinical trials for treatment of Major Depressive Disorder. Previously he was a Director in the medicinal chemistry department of Rhône-Poulenc Rorer (Sanofi-Aventis) for more than 10 years. He has 26 years’ experience in pharmaceutical R&D.
Christopher Conway is Senior Director of Business Development at AMRI, a molecular research company providing of R&D contract research services to the pharmaceutical and biotech industries with global facilities in the United States, Europe and Asia. Chris has successfully lead and implemented international sales and marketing strategies for both AMRI and various divisions of Johnson & Johnson over the past 15 years. His strong track record in business development and drug discovery stems from the development of numerous high profile deals with large pharmaceutical, biotech, non-profit, academic, agricultural, and government organizations throughout the world.
Meet The Moderator
Dr. Ving J. Lee is Chief Executive Officer and Chief Scientific Officer at Adesis, Inc., a Delaware-based organization, which provides R&D contract research services worldwide to pharmaceutical, biotech and materials sciences industries. He has extensive anti-infectives research and business expertise from Lederle Laboratories (formerly American Cyanamid), Microcide Pharmaceuticals, Iconix Biosciences, and Anacor Pharmaceuticals. Thematically, Dr. Lee’s research has encompassed i) eukaryotic systems biology considerations in the design of new molecular entities against prokaryotes based on natural product scaffolds, ii) understanding the function of eukaryotic transporters in drug deposition and metabolism, iii) prokaryotic resistance factors, and iv) applications of systems biology in translational research. On the chemistry side, he has exploited i) the subtle reactivity found with certain natural products and ii) novel heterocycles with newer synthetic methods to create new molecular entities. Dr. Lee is also a co-founder and Chief Scientific Officer of Limerick Biopharma,, focused on metabolic and orphan diseases.
The Fine Print
ACS Webinars™ does not endorse any products or services. The views expressed in this presentation are those of the presenters and do not necessarily reflect the views or policies of the American Chemical Society.